lung cancer
Conditions
Interventions
A:ETSIC+PD-1 monoantibody
B:Pemetrexed+Carboplatin+ETSIC
C:Pemetrexed + Carboplatin
Sponsors
Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Gene editing technology to screen people who benefit from ETSIC treatment; 2. Newly treated stage IV adenocarcinoma; 3. Negative driver gene; 4. PD-L1 expression is positive; 5. Have tumor tissue available for biomarker detection; 6. aged 18-75 years old; 7. PS 0-1 points; 8. Rule out symptomatic brain metastases.
Exclusion criteria
Exclusion criteria: 1) The patient has been treated with immune checkpoint inhibitors such as anti-PD-1, PD-L1 or CTLA-4 therapy; 2) Patients who have received systemic platinum dual-drug chemotherapy as advanced treatment; 3) The patient received other approved systemic anticancer therapy or systemic immunomodulators (including but not limited to interferon, interleukin 2 and tumor necrosis factor) 4 weeks before the first dose; 4) The patient is accompanied by refractory pleural fluid or ascites, such as pleural fluid or ascites that needs to be punctured and drained within 2 weeks before the first administration; 5) Active leptomeningeal disease or brain metastasis, if there are central nervous system symptoms, interventional treatment (including but not limited to radiotherapy, lowering intracranial pressure, etc.) is required.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| ORR;DCR;OS;safety; | — |
Countries
China
Contacts
Public ContactHan Baohui
Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University
Outcome results
None listed